{"disease":{"id":"unresectable-hepatocellular-carcinoma","name":"unresectable hepatocellular carcinoma"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05667064","title":"Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07204327","title":"Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1136,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT04947956","title":"Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT04770896","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":557,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07065786","title":"A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06788353","title":"Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06739317","title":"SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01015833","title":"Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06117891","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01176604","title":"Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01004978","title":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05263219","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":230,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06593964","title":"TACE With Thermosensitive Nanogel Versus Embosphere for HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT03186898","title":"Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06315101","title":"Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Guangzhou University of Chinese Medicine","has_results":false},{"nct_id":"NCT07227012","title":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05168163","title":"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06503250","title":"A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06360042","title":"Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06909708","title":"SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","phase":"NA","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06485466","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":101,"lead_sponsor_name":"Guohui Xu","has_results":false},{"nct_id":"NCT07351513","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT03942328","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07110233","title":"Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04401800","title":"Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05319431","title":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06280313","title":"Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Zhiyong Huang","has_results":false},{"nct_id":"NCT05582278","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Wen Li","has_results":false},{"nct_id":"NCT06896396","title":"Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Zhiyong Huang","has_results":false},{"nct_id":"NCT04387695","title":"SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT05507632","title":"Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05135364","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Yue Han","has_results":false},{"nct_id":"NCT03896646","title":"Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06310590","title":"Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Chengdu New Radiomedicine Technology Co. LTD.","has_results":false},{"nct_id":"NCT07511504","title":"Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07408804","title":"Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Bangladesh Medical University","has_results":false},{"nct_id":"NCT07391839","title":"MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Suzhou Mednovo Yi Medical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04175912","title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05957640","title":"Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT01900002","title":"Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07230314","title":"Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT06496815","title":"Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05630937","title":"Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Nerviano Medical Sciences","has_results":true},{"nct_id":"NCT05131698","title":"Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":31,"lead_sponsor_name":"Cancer Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT03107416","title":"Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07305428","title":"Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05214339","title":"A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":50},"guidelines":[{"drug_id":"durvalumab","guideline_body":"FDA label","recommendation":"IMFINZI in combination with tremelimumab-actl for the treatment.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}